Dose Insider / Glossary / Liraglutide

LiraglutideWhat it is, where it is sold and what it showed

Updated November 20, 2026 路 3 min read 路 VICTOZA and SAXENDA prescribing information, DailyMed

Liraglutide is a GLP-1 receptor agonist injected once a day, made by Novo Nordisk and first approved in the United States in 2010.

13.0%Victoza 1.8 mg, heart events in LEADER
Heart events in LEADERFirst heart attack, stroke or CV deathVictoza 1.8 mg13.0%Placebo14.9%Heart events in LEADERFirst heart attack, stroke or CV deathVictoza 1.8 mg13.0%Placebo14.9%

Median follow-up 3.5 years; hazard ratio 0.87.

On this page

It is sold as Victoza for type 2 diabetes in adults and children aged 10 and older, where it also lowers heart risk in adults with heart disease. At a higher dose it is sold as Saxenda for weight management. It came before semaglutide, which the same maker developed into a weekly medicine.1,2

How the molecule is built

The body's own GLP-1 lasts only 1.5 to 2 minutes in the blood, because the enzymes DPP-4 and neutral endopeptidase break it down. Liraglutide is 97% similar to human GLP-1, with arginine in place of lysine at position 34, and a 16-carbon fatty acid, palmitic acid, attached through a glutamic acid spacer at position 26. These changes make it stable against both enzymes and give it a half-life of about 13 hours after an injection under the skin, which the label calls suitable for once-daily dosing.2

Semaglutide took the same idea further, with a longer fatty acid and extra changes, and reached a half-life of about 1 week.3 That gap is the reason liraglutide is a daily shot and semaglutide a weekly one.

The two brands

BrandApproved forDaily doseYoungest age
VictozaType 2 diabetes, heart risk0.6 mg to start, up to 1.8 mg10
SaxendaWeight0.6 mg to start, 3 mg to treat12, over 60 kg

VICTOZA and SAXENDA prescribing information.1,2

Victoza starts at 0.6 mg once a day for a week, then 1.2 mg, with a step to 1.8 mg after at least another week if more blood sugar control is needed. It can be injected at any time of day, independently of meals.1 Saxenda climbs weekly from 0.6 mg to 3 mg in week 5, and adults who have not lost at least 4% of their weight by week 16 are to stop it.2 Each label warns against combining it with another liraglutide product.

The LEADER heart trial

LEADER is the trial that gave Victoza its heart indication. It enrolled 9,340 adults with type 2 diabetes and atherosclerotic cardiovascular disease and followed them for a median of 3.5 years on Victoza 1.8 mg or placebo, added to usual care.1

The Ozempic heart trial later used the same three-part outcome for semaglutide.3

Weight on liraglutide

At the Saxenda dose of 3 mg, 3,731 adults without diabetes lost 7.4% of their weight over 56 weeks, against 3.0% on placebo, and at least 5% was lost by 62.3% against 34.4%.2 That is about half of what the weekly medicines reached in their own trials, such as 14.9% on Wegovy over 68 weeks, though the trials were not run against each other.3

Side effects and warnings

The common side effects are in the stomach and gut. On Saxenda 3 mg, nausea was reported by 39.3% against 13.8% on placebo, diarrhea by 20.9% against 9.9% and vomiting by 15.7% against 3.9%.2 Both labels carry the boxed warning about thyroid C-cell tumors seen in rodents and rule out people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.1,2

Liraglutide also appears in studies of GLP-1 medicines and alcohol. A Swedish cohort found fewer hospital stays for alcohol use during liraglutide and semaglutide use; our page on alcohol on a GLP-1 covers it. Our page on Ozempic and Wegovy covers the semaglutide brands that followed.

Sources

  1. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published November 17, 2025; boxed warning and sections 1, 2 and 14. dailymed.nlm.nih.gov
  2. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published June 15, 2026; boxed warning and sections 1, 2, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
  3. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026, sections 11, 12.3 and 14.2; and WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026, section 14. U.S. Food and Drug Administration. accessdata.fda.gov

Related analyses

Log each daily dose and see your doses, weight and symptoms together.

Open Dose Insider